We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

94 hedge funds and large institutions have $59.9M invested in RAPT Therapeutics in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,300% more call options, than puts

Call options by funds: $120K | Put options by funds: $5K

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.72% less ownership

Funds ownership: 11.39%10.67% (-0.72%)

9% less funds holding

Funds holding: 10394 (-9)

38% less capital invested

Capital invested by funds: $97M → $59.9M (-$37.1M)

47% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 19

Holders
94
Holders Change
-9
Holders Change %
-8.74%
% of All Funds
1.35%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
10
Increased
29
Reduced
26
Closed
19
Calls
$120K
Puts
$5K
Net Calls
+$115K
Net Calls Change
-$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
TI
51
Trexquant Investment
Connecticut
$76.3K -$269K -13,301 -74%
PP
52
PDT Partners
New York
$74.4K -$154K -7,601 -62%
UBS Group
53
UBS Group
Switzerland
$58K +$647 +32 +0.9%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$50.9K
LP
55
LMR Partners
United Kingdom
$50.5K +$13K +643 +26%
Citigroup
56
Citigroup
New York
$45.4K +$18.3K +906 +47%
Wells Fargo
57
Wells Fargo
California
$43.2K +$14.1K +698 +35%
RAM
58
Readystate Asset Management
Illinois
$36.3K +$45.7K +2,259 New
JP Morgan Chase
59
JP Morgan Chase
New York
$33.6K +$324 +16 +0.8%
Mirae Asset Global ETFs Holdings
60
Mirae Asset Global ETFs Holdings
Hong Kong
$32.8K +$4.23K +209 +11%
CF
61
Corebridge Financial
Texas
$32.2K -$243 -12 -0.6%
QOP
62
Quinn Opportunity Partners
Virginia
$29K
PCM
63
Prelude Capital Management
New York
$28.9K +$8.84K +437 +32%
TD Asset Management
64
TD Asset Management
Ontario, Canada
$24K
Invesco
65
Invesco
Georgia
$23.4K -$1.23K -61 -4%
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
$23.2K
Group One Trading
67
Group One Trading
Illinois
$22.2K +$27.9K +1,379 New
JFG
68
Jefferies Financial Group
New York
$21K +$26.4K +1,306 New
SG Americas Securities
69
SG Americas Securities
New York
$21K +$26.8K +1,326 New
Susquehanna International Group
70
Susquehanna International Group
Pennsylvania
$20.5K -$2.37K -117 -8%
ACM
71
ADAR1 Capital Management
Texas
$15.1K
CUAMC
72
China Universal Asset Management Company
China
$13.5K +$6.59K +326 +64%
TRCT
73
Tower Research Capital (TRC)
New York
$10.6K -$13.8K -684 -51%
Royal Bank of Canada
74
Royal Bank of Canada
Ontario, Canada
$7K +$506 +25 +6%
Russell Investments Group
75
Russell Investments Group
United Kingdom
$6.39K +$4.55K +225 +131%

RAPT Hedge Fund Activity: Q3 2024 in Review

94 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2024, worth a combined $59.9M — down 38% from $97M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RAPT and 10 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 29 added.

The largest buyer was Pale Fire Capital SE, adding an estimated $1.25M. The largest seller was Morgan Stanley, cutting an estimated $2.2M.

  • 94 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2024, down from 103 in Q2 2024.
  • Funds reported $59.9M of RAPT Therapeutics stock for Q3 2024, down 38% quarter-over-quarter.
  • 10 funds opened new RAPT Therapeutics positions in Q3 2024 and 19 closed out, a net change of -9 holders.
  • The largest RAPT Therapeutics buyer in Q3 2024 was Pale Fire Capital SE, an estimated $1.25M added.
  • The largest RAPT Therapeutics seller in Q3 2024 was Morgan Stanley, an estimated $2.2M sold.

Based on aggregated 13F filings for Q3 2024.